Funding for this research was provided by:
National Institute of General Medical Sciences (P30GM131959)
Received: 28 May 2021
Accepted: 6 September 2021
First Online: 18 September 2021
: All procedures were performed according to the protocols approved by Institutional Animal Care and Use Committee (IACUC) at Clemson University, SC.
: NRV has substantial shares in Elastrin Therapeutics Inc. which has licensed elastin-targeted nanoparticle technology from Clemson University.